Cite
HARVARD Citation
Eisen, A. et al. (2017). A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis. Multiple sclerosis journal, experimental, translational and clinical. 3 (4), p. . [Online].